BRPI0815757A2 - Os genes pkib e naalad2 como alvos do tratamento e do diagnóstico do câncer de próstata - Google Patents

Os genes pkib e naalad2 como alvos do tratamento e do diagnóstico do câncer de próstata

Info

Publication number
BRPI0815757A2
BRPI0815757A2 BRPI0815757-0A2A BRPI0815757A BRPI0815757A2 BR PI0815757 A2 BRPI0815757 A2 BR PI0815757A2 BR PI0815757 A BRPI0815757 A BR PI0815757A BR PI0815757 A2 BRPI0815757 A2 BR PI0815757A2
Authority
BR
Brazil
Prior art keywords
naalad2
pkib
genes
targets
diagnosis
Prior art date
Application number
BRPI0815757-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Yusuke Nakamura
Hidewaki Nakagawa
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0815757A2 publication Critical patent/BRPI0815757A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0815757-0A2A 2007-08-24 2008-08-20 Os genes pkib e naalad2 como alvos do tratamento e do diagnóstico do câncer de próstata BRPI0815757A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95785307P 2007-08-24 2007-08-24
US3603008P 2008-03-12 2008-03-12
PCT/JP2008/065234 WO2009028521A1 (en) 2007-08-24 2008-08-20 Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis

Publications (1)

Publication Number Publication Date
BRPI0815757A2 true BRPI0815757A2 (pt) 2015-02-18

Family

ID=40387239

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815757-0A2A BRPI0815757A2 (pt) 2007-08-24 2008-08-20 Os genes pkib e naalad2 como alvos do tratamento e do diagnóstico do câncer de próstata

Country Status (10)

Country Link
US (1) US20120022128A1 (https=)
EP (1) EP2195425A4 (https=)
JP (1) JP2010536365A (https=)
KR (1) KR20100075452A (https=)
CN (1) CN101855346A (https=)
BR (1) BRPI0815757A2 (https=)
CA (1) CA2697512A1 (https=)
RU (1) RU2010111116A (https=)
TW (1) TW200920405A (https=)
WO (1) WO2009028521A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945848B2 (en) * 2009-07-31 2015-02-03 Chromocell Corporation Methods and compositions for identifying and validating modulators of cell fate
KR101164645B1 (ko) * 2011-10-07 2012-07-20 대한민국 Ｇｃｐⅱ 돌연변이를 함유하는 알츠하이머 예방 및 치료용 약학적 조성물
GB201303308D0 (en) * 2013-02-25 2013-04-10 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
GB201304612D0 (en) * 2013-03-14 2013-05-01 Cancer Rec Tech Ltd Diagnostic and prognostic biomarkers for prostate cancer and other disorders
CA2923092C (en) * 2014-01-03 2019-12-17 Koninklijke Philips N.V. Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression
KR101824303B1 (ko) 2015-08-06 2018-01-31 부경대학교 산학협력단 종이형 전립선암 진단센서, 이의 제조방법, 및 이를 이용한 전립선암 진단방법
CN114177296B (zh) * 2021-12-16 2023-05-26 上海交通大学医学院附属第九人民医院 Mpc的过表达或活性提高在制备预防和/或治疗前列腺癌的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
CA2881743A1 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1636342A4 (en) 2003-06-20 2008-10-08 Isis Pharmaceuticals Inc OLIGOMER COMPOUNDS FOR USE IN THE MODULATION OF GENES
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1733047A2 (en) * 2004-02-27 2006-12-20 Oncotherapy Science, Inc. Pin-prc transition genes
US7700573B2 (en) * 2004-03-23 2010-04-20 Oncotherapy Science, Inc. Method for diagnosing non-small lung cancer
US8283122B2 (en) * 2004-08-03 2012-10-09 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma
US8067153B2 (en) * 2005-07-27 2011-11-29 Oncotheraphy Science, Inc. Genes and polypeptides relating to prostate cancers
EP2311985A1 (en) * 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer

Also Published As

Publication number Publication date
RU2010111116A (ru) 2011-09-27
TW200920405A (en) 2009-05-16
WO2009028521A1 (en) 2009-03-05
US20120022128A1 (en) 2012-01-26
CA2697512A1 (en) 2009-03-05
CN101855346A (zh) 2010-10-06
JP2010536365A (ja) 2010-12-02
EP2195425A4 (en) 2011-01-19
KR20100075452A (ko) 2010-07-02
EP2195425A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
IL224370B (en) Combination treatment for prostate carcinoma
EP2373794A4 (en) NECTIN-4 FOR TARGET GENES TO CANCER THERAPY AND DIAGNOSIS
BRPI0821779A2 (pt) tratamento terapêutico de câncer
PL2438445T3 (pl) Sposoby diagnozowania raków gruczołu krokowego
BR112012002797A2 (pt) tratamento de câncer de próstata
HRP20180660T1 (hr) Sustavi i postupci za liječenje tkiva prostate
BR112012005594A2 (pt) tratamento de câncer
BRPI0924549A2 (pt) nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
BRPI0908129A2 (pt) Método de tratamento de câncer de próstata em estágio metastático
EP2310006A4 (en) CANCER TREATMENT
EP2125002A4 (en) TREATMENT OF SKIN CANCER
EP2318040A4 (en) THERAPY TREATED ON CANCER STAMPS
PL2171090T3 (pl) Markery ekspresji genów odporności guza na leczenie hamujące HER2
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
PL3296319T3 (pl) Sposoby leczenia nowotworu jelita grubego
EP2198021A4 (en) EBI3, DLX5, NPTX1, and CDKN3 for target genes of lung cancer therapy and diagnosis
BRPI0912683A2 (pt) tratamento de tumores metastáticos
PL2535716T3 (pl) Marker nowotworowy i cel terapeutyczny
HUE054196T2 (hu) Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére
BR112012003103A2 (pt) tratamento de células de astrócitos tumorais com inibidor de receptores de endotelina
IL240560A0 (en) Compositions and methods for the diagnosis and treatment of tumor
BRPI0815757A2 (pt) Os genes pkib e naalad2 como alvos do tratamento e do diagnóstico do câncer de próstata
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.